ASPIRE Awards for chordoma
Grant opportunity
Application deadline: 10 Dec 2026
Institute: The Mark Foundation for Cancer Research & the Chordoma Foundation
Country: Worldwide
More information: https://themarkfoundation.org/tbxt-and-beyond-aspire-awards-request-for-proposals/
The Mark Foundation for Cancer Research, in partnership with the Chordoma Foundation, is now accepting letters of intent for ASPIRE Awards focused on expanding the chordoma surfaceome.
These awards provide $500,000 over a 24-month term. The initiative aims to unlock new treatment paradigms for chordoma and other TBXT-driven cancers by targeting TBXT-derived peptides presented by MHC (pMHC) and uncovering novel, tumor-specific surface antigens.
Competitive proposals will generate broadly enabling datasets, tools, technologies, or mechanistic insights that facilitate the development of multiple therapeutic modalities.
Areas of interest include basic and translational research and preclinical proof-of-concept studies that de-risk future therapeutic development. Awardees will have access to the Chordoma Foundation’s extensive research-enabling resources and disease models.
Scope
Proposed projects should address one or more of the following:
Understanding and targeting TBXT pMHC
- Characterizing the expression, cell surface density, and immunogenicity of MHC-presented TBXT peptides across chordoma and other TBXT-expressing tumors, including those presented on HLA-E.
- Discovering, engineering, and optimizing TCRs, antibodies, or alternative binding scaffolds (e.g., miniproteins) targeting TBXT pMHC, while defining the determinants of effective target engagement and cross-reactivity to non-TBXT peptides.
- Characterizing MHC downregulation and loss in chordoma and identifying strategies to selectively enhance MHC presentation of immunogenic TBXT antigens in chordoma.
- Defining how the immunosuppressive chordoma tumor microenvironment limits the activity of surface-targeted therapies and identifying strategies to overcome these barriers and improve therapeutic efficacy.
Expanding the targetable chordoma surfaceome
- Applying cutting-edge technologies to discover or validate druggable tumor-specific surface targets in chordoma, including pan-cancer targets. Priority will be given to approaches that move beyond RNA expression profiling, including identifying protein complexes, co-expressed targets, conformational epitopes, aberrantly surface-localized proteins, post-translational modifications, glycolipids, glycans, and other noncanonical surface targets.
De-risking surface targeting approaches
- Developing widely shareable research tools and datasets to enable development of surface-targeted therapies.
- Defining potential barriers or primary resistance mechanisms to surface-targeting therapies, particularly T-cell-based therapies, and strategies for overcoming them.
Eligibility
- Applicants must be employed by a non-profit academic or research institution. Applications will be accepted from both U.S. and non-U.S. entities.
- Researchers are limited to one application as principal investigator but may be co-investigators on other proposals without limitation.
- Principal investigators must be independent researchers at their respective institutions.
Informational webinar
Register for The Mark Foundation’s informational webinar on 12 November 2026 at 11:00 EST to learn more about the grant and the application process.
How to apply
The deadline to submit your letter of intent is 17:00 ET on 10 December 2026. Click the link above to find out more!
« Back to latest grants